Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438588 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL21979446 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL2437801 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL495878 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL5930119 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL23092514 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL3169175 | 0.88 | SLC7A5 (0.42) | KMT2ASLC7A5L3MBTL1 | |
| SCHEMBL13536230 | 0.88 | CTRB1 (0.51) | NPC1RAB9AKMT2ACTRB1L3MBTL1 | |
| SCHEMBL13536301 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL12195833 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2205596-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1871739-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1599574-A4 | BIOTRANSFORMATION OF COMPOUNDS USING NON-PROKARYOTIC MICROALGAE | TETHYS RES LLC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1599574-A2 | BIOTRANSFORMATION OF COMPOUNDS USING NON-PROKARYOTIC MICROALGAE | Tethys Research LLC (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004081176-A2 | BIOTRANSFORMATION OF COMPOUNDS USING NON-PROKARYOTIC MICROALGAE | TETHYS RESEARCH LLC (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040175782-A1 | Biotransformation of compounds using non-prokaryotic microalgae | TETHYS RESEARCH LLC | 2004-09-09 | — | — | US | disclosed |
| US-5492910-A | AIDS TREATMENT | BRISTOL-MYERS SQUIBB CO. (US) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | NPC1 281/4885RAB9A 1660/4885CYP1A2 4611/4885 |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | NPC1 204/4885RAB9A 3199/4885CYP1A2 2962/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | NPC1 271/4885RAB9A 1904/4885CYP1A2 4642/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | NPC1 219/4885RAB9A 2364/4885CYP1A2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.